These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9604921)

  • 1. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
    LaRosa JC; Sneider GB; Boyle C
    Am J Cardiol; 1998 Apr; 81(8A):84F-87F. PubMed ID: 9604921
    [No Abstract]   [Full Text] [Related]  

  • 2. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J; Olsson AG; Sacks FM; Black DM; Orloff DG; Bilheimer DW
    Am J Cardiol; 1998 Apr; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory concerns at various phases of drug development.
    Aurecchia S; Orloff D; Sobel S
    Am J Cardiol; 1998 Apr; 81(8A):2F-4F. PubMed ID: 9604895
    [No Abstract]   [Full Text] [Related]  

  • 4. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of the effectiveness of hypolipidemic preparations in coronary arteriosclerosis].
    Bobkova VI; Lokshina LI; Sidakova MM; Tananova GV; Fomchenkov SI
    Kardiologiia; 1984 Sep; 24(9):54-7. PubMed ID: 6521249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of atherosclerosis with hypolipidemic and antiuricemic agents].
    Plastinina RA; Oleĭnik NA; Valeeva RM; Pavlova TN
    Sov Med; 1984; (1):83-7. PubMed ID: 6701660
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic agents for lipid metabolism disorders--with special reference to arterial diseases].
    Murakami M; Sekimoto H; Nagai T; Nakata I; Takekoshi T
    Nihon Rinsho; 1970 Mar; 28 Suppl():696-9. PubMed ID: 5430846
    [No Abstract]   [Full Text] [Related]  

  • 8. Early efficacy and safety studies.
    Sirtori CR
    Am J Cardiol; 1998 Apr; 81(8A):13F-16F. PubMed ID: 9604898
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.
    Davidson MH
    Am J Cardiol; 2001 Feb; 87(4A):1A-7A. PubMed ID: 11243600
    [No Abstract]   [Full Text] [Related]  

  • 10. Statins: underused by those who would benefit.
    Hulley SB; Grady D; Browner WS
    BMJ; 2000 Oct; 321(7267):971-2. PubMed ID: 11039939
    [No Abstract]   [Full Text] [Related]  

  • 11. [The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias].
    Oganov RG; Kiseleva NG; Aronov DM; Akhmedzhanov NM; Olfer'ev AM; Kiseleva NS; Perova NV
    Kardiologiia; 1993; 33(10):54-9, 6. PubMed ID: 8139175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effectiveness of the treatment of arteriosclerosis].
    Bobkova VI; Mazurova SV; Fomchenkov SI
    Kardiologiia; 1974 Jul; 14(7):108-13. PubMed ID: 4431129
    [No Abstract]   [Full Text] [Related]  

  • 13. Antilipemic drugs and the position of the FDA.
    Finkel MJ
    Adv Exp Med Biol; 1972; 26(0):263-5. PubMed ID: 4679645
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development.
    Orloff DG
    Am J Cardiol; 2001 Feb; 87(4A):35A-41A. PubMed ID: 11243603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the central clinical laboratory in the development of drugs for the treatment of cardiovascular disease by the modification of lipoprotein concentrations.
    Cole TG
    Am J Cardiol; 1998 Apr; 81(8A):75F-77F. PubMed ID: 9604917
    [No Abstract]   [Full Text] [Related]  

  • 16. Achieving blood lipid goals in patients with coronary artery disease.
    McKenney JM
    Am J Health Syst Pharm; 2001 Mar; 58(5):415-9. PubMed ID: 11258179
    [No Abstract]   [Full Text] [Related]  

  • 17. [The importance of determining the type of hyperlipidemia for lipotropic therapy of atherosclerosis].
    Bavina MV; Perova NV; Lobova NM; Koropova GI
    Kardiologiia; 1973 Mar; 13(3):27-33. PubMed ID: 4717180
    [No Abstract]   [Full Text] [Related]  

  • 18. Recommendations for Phase IV studies in the development of lipid-lowering drugs.
    Gregg RE
    Am J Cardiol; 1998 Apr; 81(8A):64F-66F. PubMed ID: 9604913
    [No Abstract]   [Full Text] [Related]  

  • 19. Requirements and methods for documenting diet uniformity and compliance in drug development trials.
    Held J
    Am J Cardiol; 1998 Apr; 81(8A):31F-33F. PubMed ID: 9604903
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid risk factors and the regression of atherosclerosis.
    Gotto AM
    Am J Cardiol; 1995 Jul; 76(2):3A-7A. PubMed ID: 7604793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.